TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 369515

Group type: EXPERIMENTAL
Intervention: 1.0 mg ethynodiol diacetate + 0.1 mg mestranol ('Ovulen')
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31372679

Group type: EXPERIMENTAL
Intervention: Tourniquet group (n=50)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Non-tourniquet group (n=49)
Number of subjects: 99
Study: 29189955

Group type: EXPERIMENTAL
Intervention: Intra‐ and peri‐articular blood injection (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Peri‐articular injection alone (Group B)
Number of subjects: 40
Study: 27270706

Group type: EXPERIMENTAL
Intervention: Single 20-s Wingate sprint, 3 sessions per week for 4 weeks
Number of subjects: 30
Study: 24828894

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril ± indapamide)
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 23024308

Group type: EXPERIMENTAL
Intervention: Light periodontal curettes (14 grams, 11 millimeters diameter)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Heavy periodontal curettes (34 grams, 8 millimeters diameter)
Number of subjects: 110
Study: 20979909

Group type: COMPARATOR
Intervention: CTrach group (C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laryngoscope group (D)
Number of subjects: 60
Study: 18823470

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 50 microg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 75 microg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 100 microg
Number of subjects: 103
Study: 16060416

Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention (n=27)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n=9)
Number of subjects: 36
Study: 11840080

Group type: EXPERIMENTAL
Intervention: CMV gB/MF59 vaccine (20 microg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control hepatitis A vaccine
Number of subjects: 18
Study: 10554936

Group type: EXPERIMENTAL
Intervention: Immediate induction of labour with oxytocin (Group 1)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Expectant management (Group 2)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Expectant management with spontaneous labour (Group 2B)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Expectant management with induced labour after 24 hours (Group 2A)
Number of subjects: 126
Study: 8907724

Group type: EXPERIMENTAL
Intervention: Twice-daily enteric-coated sodium valproate tablets
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Twice-daily controlled release tablets (Epilim Chrono)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Once-daily controlled release tablets (Epilim Chrono)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study: 1906610

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6866591

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (Ritalin) given with breakfast
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (Ritalin) given 30 minutes before breakfast
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 11
Study: 30360014

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg under fasted conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg under fed conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat food effect on etoricoxib
Number of subjects: 0
Study: 28566209

Group type: EXPERIMENTAL
Intervention: Half-dose TKI therapy (imatinib 200 mg daily, dasatinib 50 mg daily, or nilotinib 200 mg twice daily) for 12 months
Number of subjects: 174
Study: 26475066

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 171

Group type: COMPARATOR
Intervention: Early salvage radiation therapy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 171

Group type: COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Each additional patient accrued
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: First 5 patients accrued
Number of subjects: 171
Study: 24065371

Group type: EXPERIMENTAL
Intervention: Intervention centers
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control centers
Number of subjects: 32
Study: 22055834

Group type: EXPERIMENTAL
Intervention: Motivational intervention (PMT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined motivational and volitional intervention (PMT&APCP)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Volitional intervention (APCP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 19847160

Group type: EXPERIMENTAL
Intervention: 40 mg citalopram
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 8 mg reboxetine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17556106

Group type: EXPERIMENTAL
Intervention: Bereavement intervention program (Dan-jeon breathing sessions, self-help group activity, health check)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (only health check)
Number of subjects: 0
Study: 16246947

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study: 11826352

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BP)
Number of subjects: 24
Study: 10422927

Group type: EXPERIMENTAL
Intervention: 10 ml/kg intravenous fluid
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: 2 ml/kg intravenous fluid
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: High-risk patients (category 3 and 4)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Low-risk patients (category 1)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Monitoring bladder volumes by ultrasound
Number of subjects: 324
Study: 8665556

Group type: EXPERIMENTAL
Intervention: Apomorphine 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apomorphine 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1688044

Group type: EXPERIMENTAL
Intervention: Oxatomide gel at 5%
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dechlorpheniramine cream at 1%
Number of subjects: 27
Study: 6642380

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg orally in the evening and 400 mg intramuscularly two hours prior to induction of anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: No specific medication (Control)
Number of subjects: 30
Study: 31393399

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg or Anastrozole 1 mg once a day
Number of subjects: 0
Study: 28441993

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 683

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study: 27129610

Group type: EXPERIMENTAL
Intervention: Prenatal alcohol exposure (PAE)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Joint exposure to PAE and prenatal depressive symptoms
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Prenatal depressive symptoms
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Sexual dimorphism in joint exposures
Number of subjects: 344
Study: 24714056

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Relaxation training intervention
Number of subjects: 133
Study: 19258966

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (basal 8 mL/h, bolus 4 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.4% ropivacaine (basal 4 mL/h, bolus 2 mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.4% ropivacaine
Number of subjects: 50
Study: 15100626

Group type: EXPERIMENTAL
Intervention: Needle stimulation of active myofascial trigger points
Number of subjects: 21

Group type: COMPARATOR
Intervention: Needle stimulation of latent myofascial trigger points
Number of subjects: 21
Study: 11116103

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nitrendipine (10 mg)
Number of subjects: 38
Study: 9123707

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus estramustine phosphate (O + E)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Orchiectomy (O)
Number of subjects: 419
Study: 8322135

Group type: EXPERIMENTAL
Intervention: Open vaginal vault method with preoperative cefonicid administration
Number of subjects: 137

Group type: COMPARATOR
Intervention: Closed vaginal vault method (control group)
Number of subjects: 137
Study: 3524970

Group type: EXPERIMENTAL
Intervention: Diflunisal (500 mg twice daily)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (200 mg twice daily)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 38
Study: 31869820

Group type: EXPERIMENTAL
Intervention: SAU (sauna bathing) - 3 × 8 min at 80‐85°C
Number of subjects: 20

Group type: COMPARATOR
Intervention: PLAC (placebo condition - deidentified, pH‐balanced massage oil while passively resting)
Number of subjects: 20
Study: 27863806

Group type: COMPARATOR
Intervention: ABT‐493 25-800 mg (single doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABT‐493 200-800 mg (multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABT‐493 (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABT‐493 with food
Number of subjects: 0
Study: 27822448

Group type: EXPERIMENTAL
Intervention: Patients with endometrial cancer (EC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (patients without gynecological pathology or inflammatory disorders)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intraperitoneal fat measurement
Number of subjects: 88
Study: 24950985

Group type: EXPERIMENTAL
Intervention: Trebananib (15 mg/kg) plus weekly intravenous paclitaxel (80 mg/m²)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Placebo plus weekly intravenous paclitaxel (80 mg/m²)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Trebananib (15 mg/kg)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study: 22271764

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori treatment
Number of subjects: 3365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: Vitamin treatment
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: Garlic treatment
Number of subjects: 3365
Study: 19417716

Group type: EXPERIMENTAL
Intervention: MDMA (ecstasy) administration in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA (ecstasy) administration in squirrel monkeys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA (ecstasy) administration in both species
Number of subjects: 0
Study: 17853767

Group type: EXPERIMENTAL
Intervention: Ear point blood‐letting combined with cupping at Back‐shu points
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral administration of Tetracycline and external application of Cuochuangping Ointment
Number of subjects: 0
Study: 15172901

Group type: EXPERIMENTAL
Intervention: Direct observation of competence workshop
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 11182474

Group type: EXPERIMENTAL
Intervention: 5 mg tiagabine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9164315

Group type: EXPERIMENTAL
Intervention: Eptifibatide 135 micrograms/kg bolus followed by 0.5 microgram kg‐1 min‐1 infusion for 20‐24 h
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Eptifibatide 135 micrograms/kg bolus followed by 0.75 microgram kg‐1 min‐1 infusion for 20‐24 h
Number of subjects: 4010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Eptifibatide treatment
Number of subjects: 4010
Study: 8243223

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 2130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2130
Study: 3667060

Group type: EXPERIMENTAL
Intervention: 500 calorie protein‐sparing modified fast (PSMF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1200‐kcal balanced diet
Number of subjects: 28
Study: 28676957

Group type: EXPERIMENTAL
Intervention: Mesenteric defect closure
Number of subjects: 2507

Group type: COMPARATOR
Intervention: Non-closure
Number of subjects: 2507
Study: 27697447

Group type: COMPARATOR
Intervention: Medium adherence (MMAS‐8: 6 to <8)
Number of subjects: 8435

Group type: COMPARATOR
Intervention: Low adherence (MMAS‐8: <6)
Number of subjects: 8435

Group type: EXPERIMENTAL
Intervention: High adherence (MMAS‐8: 8)
Number of subjects: 8435
Study: 24666767

Group type: EXPERIMENTAL
Intervention: IV clonidine 2 mcg·kg(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV fentanyl 2 mcg·kg(‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (IV saline)
Number of subjects: 90
Study: 22092081

Group type: EXPERIMENTAL
Intervention: Low-dose double-blind placebo-controlled food challenge (DBPCFC) using a standardized vehicle with eight titrated protein doses from 3 μg to 1 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized challenge vehicle with processed, powdered hazelnut and celeriac
Number of subjects: 0
Study: 20649635

Group type: COMPARATOR
Intervention: Rosiglitazone (8 mg daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Structured physical exercise programme
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 18320242

Group type: EXPERIMENTAL
Intervention: ABM/P-15 flow
Number of subjects: 26

Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 26
Study: 16613261

Group type: EXPERIMENTAL
Intervention: Ligustrazine (LGT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LGT + PRO
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 12745849

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment
Number of subjects: 258

Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.05% ointment
Number of subjects: 258
Study: 10960927

Group type: EXPERIMENTAL
Intervention: Highly emotional standardized role-playing sessions (HE-SRPS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderately emotional standardized role-playing sessions (ME-SRPS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Weakly emotional standardized role-playing sessions (WE-SRPS)
Number of subjects: 25
Study: 8953103

Group type: EXPERIMENTAL
Intervention: Levofloxacin, clinafloxacin, sparfloxacin, trovafloxacin, grepafloxacin, DU-6859a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New fluoroquinolones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other fluoroquinolones
Number of subjects: 0
Study: 1444880

Group type: EXPERIMENTAL
Intervention: Acetyl levocarnitine hydrochloride (2.5 g/d for 3 months followed by 3 g/d for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetyl levocarnitine hydrochloride
Number of subjects: 30
Study: 3969859

Group type: EXPERIMENTAL
Intervention: Medically directed at-home rehabilitation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Group rehabilitation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Overall study population (including control patients)
Number of subjects: 127
Study: 29800180

Group type: EXPERIMENTAL
Intervention: Sustained supplementation with 400 IU/d of cholecalciferol until 6 months of age adjusted for prematurity
Number of subjects: 300

Group type: COMPARATOR
Intervention: Diet-limited supplementation (placebo)
Number of subjects: 300
Study: 27150293

Group type: EXPERIMENTAL
Intervention: Focal ablation with irreversible electroporation (IRE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Extended ablation with irreversible electroporation (IRE)
Number of subjects: 200
Study: 25107877

Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT)
Number of subjects: 48
Study: 22151608

Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine with efavirenz (arm 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (arm 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: zidovudine/abacavir (arm 3)
Number of subjects: 28
Study: 20012550

Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment (group 1, n=23)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: NSAIDs treatment (group 2, n=24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (healthy controls, n=27)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Comparison between group 1 and group 2
Number of subjects: 47
Study: 17071040

Group type: EXPERIMENTAL
Intervention: Angioseal device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 16287668

Group type: EXPERIMENTAL
Intervention: Fear-avoidance beliefs for work
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall return to work
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Correct predictions
Number of subjects: 93
Study: 11887533

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Super EBA
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 33

Group type: COMPARATOR
Intervention: Varnished negative control
Number of subjects: 33
Study: 9748085

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 8
Study: 7661729

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Brain-damaged hypertensive subjects
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 178
Study: 2752716

Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin, given orally twice daily for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered to four subjects
Number of subjects: 12
Study: 793549

Group type: EXPERIMENTAL
Intervention: Surgical treatment (aortocoronary bypass)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 116
Study: 30928969

Group type: COMPARATOR
Intervention: web‐based lifestyle advice only (lifestyle group)
Number of subjects: 956

Group type: COMPARATOR
Intervention: lifestyle advice plus information on estimated 10‐year coronary heart disease risk based on phenotypic characteristics (phenotypic group)
Number of subjects: 956

Group type: COMPARATOR
Intervention: lifestyle advice plus information on estimated 10‐year coronary heart disease risk based on phenotypic (phenotypic risk estimate) and genetic characteristics (genetic group)
Number of subjects: 956

Group type: COMPARATOR
Intervention: phenotypic group and genetic group
Number of subjects: 956
Study: 28183314

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 25982678

Group type: EXPERIMENTAL
Intervention: Thiamine supplementation (3 × 100 mg/day for six weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22562227

Group type: EXPERIMENTAL
Intervention: Webinars (WL)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Participatory learning (PL)
Number of subjects: 58
Study: 21788954

Group type: EXPERIMENTAL
Intervention: WISCI II level with no devices or braces and 1 person assistance
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Walking with assistance
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Walking without assistance and more devices
Number of subjects: 42
Study: 19657891

Group type: EXPERIMENTAL
Intervention: Internet-based asthma monitoring and data collection system
Number of subjects: 323
Study: 17034435

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 15624735

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and blue light (405-420 nm) for 15 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and intense pulsed light (IPL, 500-1,200 nm)
Number of subjects: 12
Study: 10843478

Group type: EXPERIMENTAL
Intervention: Colposcopy and cytology
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Colposcopy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Colposcopy after therapy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: HPV-DNA testing by PCR
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: HPV-DNA testing
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: CD4+ T-lymphocytes
Number of subjects: 322
Study: 9171795

Group type: EXPERIMENTAL
Intervention: Coaxial catheter method for sequential spiral CT during arterial portography (CTAP) and hepatic arteriography (CTA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of CTAP and CTA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coaxial catheter method
Number of subjects: 16
Study: 8266220

Group type: EXPERIMENTAL
Intervention: Permethrin-treated nets
Number of subjects: 399

Group type: COMPARATOR
Intervention: Untreated nets
Number of subjects: 399
Study: 3519348

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 3281786

Group type: EXPERIMENTAL
Intervention: Oral verapamil alone at a dose of 80 mg three times daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of 40 mg of verapamil three times daily with 0.25 mg of digoxin daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 8